arrow
N

Nicole Brighi

department of medical oncology
H指数:22
被引数:1,519

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy

基线血清癌胚抗原(CEA)是接受177Lu-PSMA治疗的转移性去势抵抗性前列腺癌(mCRPC)患者的独立预后生物标志物

2026-09-110
OAAI
Prognostic impact of variants of uncertain significance (VUS) in BRCA genes and homologous recombination repair (HRR) genes in prostate cancer: a real-world multicenter study

BRCA基因和同源重组修复(HRR)基因中意义不明的变异(VUS)对前列腺癌预后的影响:一项真实世界多中心研究

2026-08-040
OA
Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor–targeting therapy

脂质组学分析在转移性前列腺癌中捕获了肿瘤代谢重编程及其通过雄激素受体靶向治疗的调节

2026-03-130
OAAI
Risk of myelodysplastic syndrome and acute myeloid leukemia related to PARP inhibitor maintenance line in real-world ovarian cancer patients

与PARP抑制剂维持治疗线相关的骨髓增生异常综合征和急性髓系白血病的风险,在真实世界卵巢癌患者中的研究

2025-09-010
OAAI
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience

真实世界结局与分子分型:肺转移性去势抵抗性前列腺癌患者的长期多中心研究经验

2025-06-010
OAAI
Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial

进展性前列腺癌患者开始使用多西他赛联合或不联合恩扎卢替尼时的液体活检:PRESIDE 3b期试验的生物标志物研究

2025-02-011
OAAI
Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study)

开放标签、多中心随机试验,比较镭223-多西他赛与多西他赛-镭223序贯疗法在转移性去势抵抗性前列腺癌(mCRPC)中的应用(并前瞻性评估生物标志物)(RAPSON研究)

2024-09-010
PRE
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients
2024-08-290
OAAI
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study
2024-03-014
OAAI
Dynamics of plasma tumour DNA and copy number alterations in advanced metastatic castration-resistant prostate cancer (mCRPC) patients treated with cabazitaxel: A prospective biomarker trial
2023-10-010
OA